UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 138

Sortiert nach

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4743-4750

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3284-3289

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Link zum Volltext

Verfügbarkeit prüfen

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy

Cancers, 2021-03, Vol.13 (6), p.1426

2021

Link zum Volltext

Verfügbarkeit prüfen

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

Clinical cancer research, 2007-08, Vol.13 (15), p.4606s-4612s

2007

Link zum Volltext

Verfügbarkeit prüfen

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285

2019

Link zum Volltext

Verfügbarkeit prüfen

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3936-3944

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clinical cancer research, 2012-06, Vol.18 (11), p.3163-3169

2012

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer

Annals of surgical oncology, 2019-11, Vol.26 (12), p.3807-3808

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

Current medical research and opinion, 2020-09, Vol.36 (9), p.1497-1505

2020

Link zum Volltext

Verfügbarkeit prüfen

The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer

Journal of cachexia, sarcopenia and muscle, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment of advanced squamous cell carcinoma of the lung: a review

Translational lung cancer research, 2015-10, Vol.4 (5), p.524-532

2015

Link zum Volltext

Verfügbarkeit prüfen

Implications of key trials in advanced nonsmall cell lung cancer

Cancer, 2010-03, Vol.116 (5), p.1155-1164

Bonomi, Philip D.

2010

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.126-130

2017

Link zum Volltext

Verfügbarkeit prüfen

Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy

Journal of neuromuscular diseases, 2017, Vol.4 (2), p.169-173

2017

Link zum Volltext

Verfügbarkeit prüfen

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Radiotherapy and oncology, 2006-11, Vol.81 (2), p.163-167

2006

Link zum Volltext

Verfügbarkeit prüfen

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Clinical cancer research, 2007-08, Vol.13 (15), p.4583s-4588s

2007

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.338-345

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

Journal of thoracic oncology, 2016-09, Vol.11 (9), p.1387-1396

2016

Link zum Volltext

Verfügbarkeit prüfen

Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer

Expert review of anticancer therapy, 2010-10, Vol.10 (10), p.1589-1599

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of weight gain and overall survival of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9088-9088

2022

Link zum Volltext

Verfügbarkeit prüfen

Gender and weight change, skeletal muscle index(SMI) change, and survival in advanced non-small cell lung cancer(NSCLC) patients(pts.) receiving platinum chemotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24080-e24080

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer cachexia impact on chemotherapy dose reduction, treatment discontinuation, and survival: A qualitative systematic review

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24103-e24103

2022

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Advances in Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Clinical lung cancer, 2004-11, Vol.6 (3), p.154-161

Bonomi, Philip D.

2004

Link zum Volltext

Verfügbarkeit prüfen

Current strategies in the management of lung cancer

Oncology (Williston Park, N.Y.), 2005-11, Vol.19 (13), p.1667-1668

Bonomi, Philip D

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(136)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(72)
Science & Technology
(72)
Life Sciences & Biomedicine
(71)
Oncology
(56)
Male
(44)
Female
(43)
Middle Aged
(43)
Aged
(42)
Lung Neoplasms - Drug Therapy
(38)
Adult
(35)
Biological And Medical Sciences
(33)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(33)
Medical Sciences
(33)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Treatment Outcome
(22)
Lung Neoplasms - Pathology
(20)
Pneumology
(20)
Respiratory System
(19)
Tumors Of The Respiratory System And Mediastinum
(19)
Aged, 80 And Over
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer

Treatment of advanced squamous cell carcinoma of the lung: a review

Implications of key trials in advanced nonsmall cell lung cancer

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer

Evaluation of weight gain and overall survival of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy

Gender and weight change, skeletal muscle index(SMI) change, and survival in advanced non-small cell lung cancer(NSCLC) patients(pts.) receiving platinum chemotherapy

Cancer cachexia impact on chemotherapy dose reduction, treatment discontinuation, and survival: A qualitative systematic review

Therapeutic Advances in Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Current strategies in the management of lung cancer

Suchergebnisse filtern